Remdesivir: A Classic Analysis of Desperate Measures During Desperate Times
An analysis of the surge in demand for Remdesivir, as a COVID-19 drug. Was the surge driven by market preferences, perception, and push by few people? The rise of Remdesivir in 2020 is a classic example of what social media sentiments, medical data (or sales without medical data), and public perception are capable of doing in desperate times.
The three “P” were perception, preferences, and push that drove more drug sales and in turn benefited few while risking the lives of many.
According to HHS, the US had secured >500,000 treatment courses of Remdesivir in September 2020. This has exhausted the stock of Gilead for 3 months.
Recently, HEOR has put the cost of COVID intensive-care treatment at around USD 20,000. If the drug shortens an ICU stay by 30%, then there might be a justification for a USD 5,000 price for the drug.